Sigilon Therapeutics (SGTX) 10-Q2022 Q1 Quarterly report

Filed: 12 May 22, 4:26pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: apparent, asset, ATM, barrier, bid, border, brain, Brazilian, Canaccord, clearance, consecutive, corroborated, delisted, detailed, enzyme, fibrotic, furnish, Genuity, hierarchy, ICE, leader, legacy, minimum, modulate, morale, Nasdaq, neurological, OTC, overgrowth, overnight, Oxley, penetrate, pericapsular, persuading, PFO, physiology, plasma, quoted, readily, reduction, regain, repo, resemble, Reserve, retaliatory, retrieval, reveal, SOFR, steering, suppression, thereto, Ukraine, unadjusted, understood, unintended, unobservable, unplanned, unqualified, valuation, York

Removed: accessibility, actively, adjusted, advancement, afflicted, AG, AGAL, Aid, anniversary, automatically, Bayer, Behring, bleeding, bore, borrowed, capable, cassette, China, commerce, computing, confirmed, constantly, contractually, conversion, converted, CSL, customize, cyber, dealing, declining, depth, designate, disappear, distributed, diverse, documenting, downturn, effected, engine, expansion, explore, expression, floating, floor, flow, formal, fourth, fresh, function, FVIID, globally, growing, healthy, holder, home, immunosuppression, improving, infection, inherited, interrupt, involuntarily, justified, Leveraging, lysosome, mannose, mediated, metabolic, moderate, monthly, nonemployee, Octapharma, operation, Pacific, par, participating, Pfizer, predicted, premarketing, President, prevention, prime, ratio, reallocate, reclassified, recovered, reformed, remeasure, remotely, repayable, repurchase, retroactive, reviewing, Roche, save, SOX, stimulate, strain, structure, studying, surfaced, Takeda, talent, taxation, team, train, transit, Trump, undistributed, urge, vested, voluntarily, weak, Western, worker, workplace, worsen, Wuhan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SGTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Sigilon Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that to the best of his knowledge:


	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: May 12, 2022	By:	/s/ Rogerio Vivaldi Coelho, M.D.
		Rogerio Vivaldi Coelho, M.D. President and Chief Executive Officer (Principal Executive Officer)



Date: May 12, 2022	By:	/s/ Josias Pontes
		Josias Pontes Senior Vice President, Acting Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.